Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:sorafenib
go back to main search page
Accession:CHEBI:50924 term browser browse the term
Definition:A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group.
Synonyms:exact_synonym: 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
 related_synonym: 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide;   Formula=C21H16ClF3N4O3;   InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31);   InChIKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N;   N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea;   SMILES=C1(=C(C=C(C=C1)NC(NC2=CC=C(C=C2)OC3=CC=NC(=C3)C(NC)=O)=O)C(F)(F)F)Cl;   sorafenibum
 alt_id: CHEBI:47228
 xref: CAS:284461-73-0;   DrugBank:DB00398;   Drug_Central:2459;   KEGG:D08524;   LINCS:LSM-1008
 xref_mesh: MESH:C471405
 xref: PDBeChem:BAX;   Wikipedia:Sorafenib


show annotations for term's descendants           Sort by:
 
sorafenib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO sorafenib results in decreased activity of ABCB11 protein CTD PMID:20829430 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 affects response to substance ISO ABCC1 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 affects response to substance ISO ABCC2 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 affects response to substance ISO ABCC3 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions
decreases phosphorylation
decreases activity
ISO sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased phosphorylation of ABL1 protein mutant form
sorafenib results in decreased activity of ABL1 protein mutant form
CTD PMID:19366808 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression EXP sorafenib results in decreased expression of ACTA2 mRNA CTD PMID:24321339 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Actg2 actin gamma 2, smooth muscle decreases expression EXP sorafenib results in decreased expression of ACTG2 mRNA CTD PMID:19338580 NCBI chr 4:115,215,160...115,239,746
Ensembl chr 4:115,215,060...115,239,723
JBrowse link
G Afp alpha-fetoprotein multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] CTD PMID:29859236 NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions
affects localization
ISO [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] affects the localization of AIFM1 protein; [sorafenib co-treated with 6-bromoindirubin-3'-oxime] affects the localization of AIFM1 protein; [sorafenib co-treated with TNFSF10 protein] affects the localization of AIFM1 protein; GSK3B inhibits the reaction [sorafenib affects the localization of AIFM1 protein]
Sorafenib affects the localization of AIFM1 protein
CTD PMID:16109713, PMID:16959960, PMID:17909059, PMID:17991738, PMID:20054642, PMID:20117835 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation
decreases phosphorylation
ISO 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in decreased phosphorylation of AKT1 protein]; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Oxygen deficiency affects the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in decreased phosphorylation of AKT1 protein]]
Sorafenib results in increased phosphorylation of AKT1 protein
CTD PMID:16985072, PMID:21858812, PMID:23036488 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
ISO [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; sorafenib promotes the reaction [ATF4 protein results in increased expression of DDIT4 protein]
[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 mRNA; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 protein; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein; sorafenib results in increased expression of ATF4 mRNA; sorafenib results in increased expression of ATF4 protein
CTD PMID:21601561 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atg5 autophagy related 5 multiple interactions
increases expression
ISO [Sorafenib co-treated with Vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [Sorafenib co-treated with Vorinostat] results in increased expression of ATG5 protein; ATG5 protein inhibits the reaction [[Sorafenib co-treated with Vorinostat] results in increased cleavage of CASP8 protein]; EIF2AK3 protein promotes the reaction [[Sorafenib co-treated with Vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in increased expression of ATG5 protein]; FADD protein promotes the reaction [[Sorafenib co-treated with Vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in decreased expression of ATG5 protein]; FAS protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in decreased expression of ATG5 protein]
sorafenib results in increased expression of ATG5 protein
CTD PMID:18787411 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Bad BCL2-associated agonist of cell death increases expression
decreases expression
ISO sorafenib results in increased expression of BAD protein
sorafenib results in decreased expression of BAD mRNA
CTD PMID:18200035, PMID:21360571 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bak1 BCL2-antagonist/killer 1 decreases expression
multiple interactions
increases expression
ISO sorafenib results in decreased expression of BAK1 protein
[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; sorafenib promotes the reaction [destruxin B results in increased expression of BAK1 protein]
sorafenib results in increased expression of BAK1 protein
CTD PMID:16109713, PMID:17909059, PMID:18200035, PMID:24434019 NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
decreases expression
increases cleavage
increases expression
ISO [sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein; [sorafenib co-treated with TNFSF10 protein] affects the localization of BAX protein; BCL2L1 protein inhibits the reaction [sorafenib affects the folding of and results in increased activity of BAX protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]; sorafenib affects the folding of and results in increased activity of BAX protein
sorafenib results in decreased expression of BAX mRNA
sorafenib results in increased cleavage of BAX protein
sorafenib results in increased expression of BAX protein
CTD PMID:16109713, PMID:17909059, PMID:18200035, PMID:19366808, PMID:21360571 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases response to substance
increases cleavage
decreases expression
ISO [Paclitaxel co-treated with sorafenib] results in decreased expression of BCL2 protein; [sorafenib co-treated with Vitamin K 1] results in decreased expression of BCL2 protein; resveratrol promotes the reaction [sorafenib results in decreased expression of BCL2 protein]; sorafenib inhibits the reaction [Acids results in increased expression of BCL2 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of BCL2 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of BCL2 protein]
BCL2 protein results in decreased susceptibility to sorafenib
sorafenib results in increased cleavage of BCL2 protein
sorafenib results in decreased expression of BCL2 mRNA; sorafenib results in decreased expression of BCL2 protein
CTD PMID:16109713, PMID:17991738, PMID:18512153, PMID:19664330, PMID:19878585, PMID:20301194, PMID:20881478, PMID:24434019, PMID:26409325, PMID:26911335, PMID:28673964 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
ISO [sorafenib co-treated with TNFSF10 protein] results in decreased expression of BCL2L1 protein; BCL2L1 protein inhibits the reaction [sorafenib affects the folding of and results in increased activity of BAX protein]; BCL2L1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; resveratrol promotes the reaction [sorafenib results in decreased expression of BCL2L1 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of BCL2L1 protein]
Sorafenib results in decreased expression of BCL2L1 protein
CTD PMID:16109713, PMID:17909059, PMID:17991738, PMID:19366808, PMID:19633425, PMID:24434019, PMID:26911335 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 affects localization
increases expression
decreases expression
multiple interactions
ISO sorafenib affects the localization of BCL2L11 protein
sorafenib results in increased expression of BCL2L11 protein
sorafenib results in decreased expression of BCL2L11 protein
[sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased expression of BCL2L11 protein
CTD PMID:16109713, PMID:18200035, PMID:23036488 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bcr BCR activator of RhoGEF and GTPase multiple interactions
decreases phosphorylation
decreases activity
ISO sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased phosphorylation of BCR protein mutant form
sorafenib results in decreased activity of BCR protein mutant form
CTD PMID:19366808 NCBI chr20:14,421,250...14,546,406
Ensembl chr20:14,421,141...14,545,772
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of BID protein CTD PMID:17909059, PMID:20301194 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression ISO sorafenib results in decreased expression of BIRC3 protein CTD PMID:20473320 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression
ISO [[[Sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[Sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [Resveratrol co-treated with Sorafenib] results in decreased expression of BIRC5 protein; Sorafenib inhibits the reaction [IGF1 protein results in increased expression of BIRC5 protein]
sorafenib analog results in decreased expression of BIRC5 protein; sorafenib results in decreased expression of BIRC5 mRNA; sorafenib results in decreased expression of BIRC5 protein
CTD PMID:18200035, PMID:20473320, PMID:21531053, PMID:21601561, PMID:26172295, PMID:26409325, PMID:26911335 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions
decreases activity
ISO
EXP
Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]
sorafenib results in decreased activity of BRAF protein
sorafenib results in decreased activity of BRAF protein; sorafenib results in decreased activity of BRAF protein mutant form
CTD PMID:17341847, PMID:17664273, PMID:20823850 NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
decreases expression
increases cleavage
increases activity
affects cleavage
ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein; [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased cleavage of CASP3 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in increased cleavage of CASP3 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of CASP3 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein; [sorafenib co-treated with vorinostat] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; arsenic trioxide promotes the reaction [sorafenib results in decreased expression of CASP3 protein]; arsenic trioxide promotes the reaction [sorafenib results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; resveratrol promotes the reaction [sorafenib results in increased cleavage of CASP3 protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased activity of CASP3 mRNA]; sorafenib promotes the reaction [arsenic trioxide results in decreased expression of CASP3 protein]; sorafenib promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]; sorafenib results in increased cleavage of and results in increased activity of CASP3 protein
Sorafenib results in increased expression of CASP3 protein modified form
sorafenib results in decreased expression of CASP3 mRNA
sorafenib affects the cleavage of CASP3 protein
CTD PMID:16007148, PMID:16109713, PMID:16985072, PMID:17909059, PMID:18200035, PMID:18787411, PMID:19366808, PMID:19770576, PMID:20071162, PMID:20117835, PMID:20301194, PMID:20473320, PMID:21293487, PMID:21360571, PMID:23036488, PMID:25416439, PMID:26409325, PMID:26911335, PMID:28673964, PMID:32634519 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 increases activity
multiple interactions
ISO sorafenib results in increased activity of CASP7 protein
[sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP7 protein; sorafenib results in increased cleavage of and results in increased activity of CASP7 protein
CTD PMID:16109713, PMID:17909059, PMID:19770576, PMID:20054642 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
affects localization
ISO [sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP8 protein; [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein; ATG5 protein inhibits the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; Boc-D-FMK inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP8 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; sorafenib results in increased cleavage of and results in increased activity of CASP8 protein
sorafenib results in increased cleavage of CASP8 protein
sorafenib affects the localization of CASP8 protein modified form
CTD PMID:16007148, PMID:16109713, PMID:17909059, PMID:18200035, PMID:18787411, PMID:20071162, PMID:20301194 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions
increases cleavage
increases activity
ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in increased cleavage of CASP9 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; arsenic trioxide promotes the reaction [sorafenib results in increased activity of CASP9 protein]; MCL1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP9 protein]; sorafenib promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]; sorafenib results in increased cleavage of and results in increased activity of CASP9 protein
sorafenib results in increased cleavage of CASP9 protein
CTD PMID:16109713, PMID:16985072, PMID:17909059, PMID:18200035, PMID:20054642, PMID:20071162, PMID:20117835, PMID:21293487, PMID:25416439 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Ccn2 cellular communication network factor 2 decreases expression ISO Sorafenib results in decreased expression of CCN2 mRNA CTD PMID:21360571 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccna2 cyclin A2 decreases expression ISO sorafenib results in decreased expression of CCNA2 protein CTD PMID:19139124 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO sorafenib results in decreased expression of CCNB1 protein CTD PMID:19139124 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions
ISO
EXP
sorafenib analog results in decreased expression of CCND1 protein; sorafenib results in decreased expression of CCND1 mRNA; sorafenib results in decreased expression of CCND1 protein
Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA]
sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein]; sorafenib inhibits the reaction [TSC2 protein mutant form results in increased expression of CCND1 protein]
[sorafenib co-treated with letrozole] results in decreased expression of CCND1 protein; [sorafenib co-treated with rottlerin] results in decreased expression of CCND1 protein; arsenic trioxide promotes the reaction [sorafenib results in decreased expression of CCND1 protein]; sorafenib inhibits the reaction [Acids results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Acids results in increased expression of CCND1 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]; sorafenib promotes the reaction [arsenic trioxide results in decreased expression of CCND1 protein]
CTD PMID:16959960, PMID:17178882, PMID:17909054, PMID:18512153, PMID:18840136, PMID:19001435, PMID:19633425, PMID:19878585, PMID:20054642, PMID:21531053, PMID:21693435, PMID:21813464, PMID:25416439, PMID:29859236 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO sorafenib results in decreased expression of CCND2 protein CTD PMID:19001435 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Ccnd3 cyclin D3 multiple interactions
decreases expression
ISO [sorafenib co-treated with rottlerin] results in decreased expression of CCND3 protein
sorafenib results in decreased expression of CCND3 protein
CTD PMID:16959960, PMID:19001435 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO sorafenib inhibits the reaction [Acids results in increased expression of CCNE1 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein] CTD PMID:18512153 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression
ISO sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; sorafenib promotes the reaction [destruxin B results in increased expression of CDH1 protein]
sorafenib results in increased expression of CDH1 protein
CTD PMID:21360571, PMID:24434019 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO sorafenib promotes the reaction [destruxin B results in decreased expression of CDH2 protein] CTD PMID:24434019 NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression ISO sorafenib results in decreased expression of CDK1 protein CTD PMID:19139124 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression ISO sorafenib results in decreased expression of CDK2 mRNA CTD PMID:26409325 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions
decreases expression
ISO [sorafenib co-treated with rottlerin] results in decreased expression of CDK4 protein
sorafenib results in decreased expression of CDK4 protein
CTD PMID:16959960 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression
ISO [sorafenib co-treated with rottlerin] results in decreased expression of CDK6 protein
sorafenib results in decreased expression of CDK6 protein
CTD PMID:16959960 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
JBrowse link
G Cdk9 cyclin-dependent kinase 9 decreases expression ISO sorafenib results in decreased expression of CDK9 mRNA CTD PMID:26409325 NCBI chr 3:11,742,269...11,747,117
Ensembl chr 3:11,742,266...11,747,113
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression ISO sorafenib results in decreased expression of CDKN1A protein CTD PMID:19139124 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
decreases expression
increases expression
ISO
EXP
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in increased expression of CDKN1B protein]; sorafenib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of CDKN1B protein]
sorafenib results in decreased expression of CDKN1B protein
sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein]
CTD PMID:19139124, PMID:19878585, PMID:21693435, PMID:23036488 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B increases expression ISO sorafenib results in increased expression of CDKN2B protein CTD PMID:19139124 NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions
increases expression
ISO sorafenib promotes the reaction [CEBPD protein binds to GADD45G promoter]
sorafenib results in increased expression of CEBPD protein
CTD PMID:26172295 NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression
increases degradation
multiple interactions
ISO sorafenib results in decreased expression of CFLAR protein
sorafenib results in increased degradation of CFLAR protein
[sorafenib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [sorafenib results in decreased expression of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib results in increased degradation of CFLAR protein] which results in increased susceptibility to TNFSF10 protein
CTD PMID:17909059, PMID:20071162 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions
decreases expression
ISO
EXP
sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]
sorafenib results in decreased expression of COL1A1 mRNA
CTD PMID:21360571, PMID:24321339 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 protein] CTD PMID:21360571 NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
JBrowse link
G Col4a1 collagen type IV alpha 1 chain multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL4A1 protein] CTD PMID:21360571 NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions
decreases phosphorylation
ISO sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased phosphorylation of CRKL protein
CTD PMID:19366808 NCBI chr11:87,338,606...87,356,644
Ensembl chr11:87,778,312...87,815,043
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO sorafenib promotes the reaction [destruxin B results in decreased expression of CTNNB1 protein] CTD PMID:24434019 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cycs cytochrome c, somatic affects localization ISO sorafenib affects the localization of CYCS protein CTD PMID:16007148 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase increases expression ISO [sorafenib results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein; sorafenib results in increased expression of CYLD mRNA; sorafenib results in increased expression of CYLD protein CTD PMID:21109933 NCBI chr19:19,264,984...19,323,817
Ensembl chr19:19,265,164...19,315,357
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 mRNA; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 protein; sorafenib results in increased expression of DDIT3 mRNA; sorafenib results in increased expression of DDIT3 protein CTD PMID:17548474, PMID:21601561 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 multiple interactions
increases expression
ISO [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; sorafenib promotes the reaction [ATF4 protein results in increased expression of DDIT4 protein]
[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein; sorafenib results in increased expression of DDIT4 protein
CTD PMID:21601561 NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions
affects localization
ISO 6-bromoindirubin-3'-oxime promotes the reaction [sorafenib affects the localization of DIABLO protein]; [sorafenib co-treated with TNFSF10 protein] affects the localization of DIABLO protein; GSK3B inhibits the reaction [sorafenib affects the localization of DIABLO protein]
Sorafenib affects the localization of DIABLO protein
CTD PMID:17909059, PMID:17991738 NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
JBrowse link
G Dok1 docking protein 1 decreases phosphorylation ISO sorafenib results in decreased phosphorylation of DOK1 protein CTD PMID:19366808 NCBI chr 4:113,864,211...113,866,695
Ensembl chr 4:113,864,215...113,866,674
JBrowse link
G Egf epidermal growth factor multiple interactions ISO [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:17664273, PMID:21187475 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor decreases expression ISO sorafenib results in decreased expression of EGFR mRNA CTD PMID:26409325 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A multiple interactions
increases phosphorylation
ISO [sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]
sorafenib results in increased phosphorylation of EIF2A protein
CTD PMID:17548474, PMID:18787411, PMID:19366808 NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions
increases phosphorylation
ISO [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to EIF2AK3 protein]; [sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased expression of ATG5 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]
sorafenib results in increased phosphorylation of EIF2AK3 protein
CTD PMID:17548474, PMID:18787411 NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
JBrowse link
G Eif4e eukaryotic translation initiation factor 4E multiple interactions
decreases phosphorylation
ISO [sorafenib results in decreased phosphorylation of EIF4E protein] which results in decreased expression of MCL1; sorafenib inhibits the reaction [MKNK1 protein results in increased phosphorylation of EIF4E protein] CTD PMID:16109713, PMID:21750559 NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
increases phosphorylation
decreases phosphorylation
ISO
EXP
[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib] results in decreased phosphorylation of EIF4EBP1 protein; arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of EIF4EBP1 protein]
sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of EIF4EBP1 protein modified form]
Sorafenib results in decreased phosphorylation of EIF4EBP1 protein
CTD PMID:16255777, PMID:20054642, PMID:21601561, PMID:21813464, PMID:21858812, PMID:23036488, PMID:25416439 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Fadd Fas associated via death domain multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in decreased expression of ATG5 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein] CTD PMID:18787411 NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
JBrowse link
G Fas Fas cell surface death receptor multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to EIF2AK3 protein]; [vorinostat co-treated with sorafenib] affects the localization of FAS protein; [vorinostat co-treated with sorafenib] results in increased activity of FAS protein; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in decreased expression of ATG5 protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]; fumonisin B1 inhibits the reaction [[sorafenib co-treated with vorinostat] affects the localization of and results in increased activity of FAS protein]; SMPD1 protein promotes the reaction [[vorinostat co-treated with sorafenib] affects the localization of FAS protein]; thermozymocidin inhibits the reaction [[sorafenib co-treated with vorinostat] affects the localization of and results in increased activity of FAS protein] CTD PMID:18787411 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Faslg Fas ligand multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein] CTD PMID:20301194 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Flt3 Fms related receptor tyrosine kinase 3 increases response to substance
decreases phosphorylation
multiple interactions
decreases activity
ISO FLT3 protein results in increased susceptibility to sorafenib
sorafenib results in decreased phosphorylation of FLT3 protein mutant form
[sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of FLT3 protein mutant form; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of FLT3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK3 protein; sorafenib inhibits the reaction [FLT3 protein mutant form results in increased phosphorylation of FLT3 protein mutant form]
sorafenib results in decreased activity of FLT3 protein; sorafenib results in decreased activity of FLT3 protein mutant form
CTD PMID:17205056, PMID:17229632, PMID:21482694, PMID:22409268, PMID:23036488 NCBI chr12:9,360,439...9,437,004
Ensembl chr12:9,360,672...9,436,570
JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] CTD PMID:21360571 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta multiple interactions
increases expression
increases response to substance
ISO pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B mRNA]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B protein]; sorafenib promotes the reaction [JUN protein binds to GADD45B promoter]; sorafenib results in increased expression of and results in increased localization of GADD45B protein
GADD45B protein results in increased susceptibility to sorafenib
CTD PMID:21062976 NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma decreases response to substance
increases expression
multiple interactions
ISO GADD45G mutant form results in decreased susceptibility to sorafenib
sorafenib results in increased expression of GADD45G mRNA; sorafenib results in increased expression of GADD45G protein
sorafenib promotes the reaction [CEBPD protein binds to GADD45G promoter]
CTD PMID:26172295 NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions
increases secretion
ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein]
Sorafenib results in increased secretion of GPT protein
CTD PMID:29655783, PMID:29859236 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Grb2 growth factor receptor bound protein 2 decreases expression ISO sorafenib results in decreased expression of GRB2 mRNA CTD PMID:26409325 NCBI chr10:104,193,953...104,263,071
Ensembl chr10:104,193,955...104,263,071
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
increases phosphorylation
ISO arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of GSK3B protein]; GSK3B inhibits the reaction [sorafenib affects the localization of AIFM1 protein]; GSK3B inhibits the reaction [sorafenib affects the localization of DIABLO protein]; sorafenib inhibits the reaction [arsenic trioxide results in decreased phosphorylation of GSK3B protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of MYC protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of TP53 protein]; sorafenib results in decreased phosphorylation of and results in increased activity of GSK3B protein CTD PMID:17991738, PMID:25416439 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Hdac6 histone deacetylase 6 decreases expression ISO sorafenib results in decreased expression of HDAC6 mRNA CTD PMID:26409325 NCBI chr  X:15,295,372...15,316,673
Ensembl chr  X:15,295,473...15,316,671
JBrowse link
G Hgf hepatocyte growth factor decreases response to substance
multiple interactions
ISO HGF protein results in decreased susceptibility to Sorafenib
Plant Extracts inhibits the reaction [HGF protein results in decreased susceptibility to Sorafenib]
CTD PMID:32522589 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha decreases expression ISO sorafenib results in decreased expression of HIF1A mRNA CTD PMID:26409325 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]] CTD PMID:18787411 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO sorafenib inhibits the reaction [IGF1 protein results in increased expression of BIRC5 protein] CTD PMID:21601561 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Igf1r insulin-like growth factor 1 receptor decreases expression ISO sorafenib results in decreased expression of IGF1R mRNA CTD PMID:26409325 NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
JBrowse link
G Irf5 interferon regulatory factor 5 increases expression ISO sorafenib results in increased expression of IRF5 mRNA CTD PMID:26409325 NCBI chr 4:56,804,477...56,816,271
Ensembl chr 4:56,805,132...56,820,543
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; [sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of JUN protein]; sorafenib promotes the reaction [JUN protein binds to GADD45B promoter]; sorafenib results in increased expression of and results in increased phosphorylation of and results in increased localization of JUN protein CTD PMID:16985072, PMID:20301194, PMID:21062976 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO sorafenib results in decreased activity of KCNH2 protein CTD PMID:28551711 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Kdr kinase insert domain receptor multiple interactions
decreases phosphorylation
ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein
sorafenib results in decreased phosphorylation of KDR protein
CTD PMID:16985072, PMID:19139124 NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase decreases phosphorylation ISO sorafenib results in decreased phosphorylation of KIT protein CTD PMID:19139124 NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase decreases phosphorylation ISO sorafenib results in decreased phosphorylation of LCK protein CTD PMID:21293487 NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions
decreases phosphorylation
ISO
EXP
[MAP2K1 protein results in increased phosphorylation of MAPK1 protein] which results in decreased susceptibility to sorafenib; [MAP2K1 protein results in increased phosphorylation of MAPK3 protein] which results in decreased susceptibility to sorafenib; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]
sorafenib results in decreased phosphorylation of MAP2K1 protein
CTD PMID:17341847, PMID:18200035, PMID:19139124, PMID:20117835, PMID:21187475 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions
decreases phosphorylation
ISO
EXP
[sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]
sorafenib results in decreased phosphorylation of MAP2K2 protein
CTD PMID:17341847, PMID:18200035, PMID:21187475 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions
decreases phosphorylation
ISO licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAP2K4 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAP2K4 protein] CTD PMID:30187994 NCBI chr10:52,196,121...52,301,887
Ensembl chr10:52,196,124...52,290,657
JBrowse link
G Mapk1 mitogen activated protein kinase 1 affects phosphorylation
increases phosphorylation
decreases phosphorylation
multiple interactions
decreases expression
decreases activity
ISO
EXP
sorafenib affects the phosphorylation of MAPK1 protein
sorafenib results in increased phosphorylation of MAPK1 protein
sorafenib results in decreased phosphorylation of MAPK1 protein
Sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK1 protein modified form]; Sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
sorafenib results in decreased expression of MAPK1 protein modified form
Sorafenib results in decreased phosphorylation of MAPK1 protein
sorafenib results in decreased activity of MAPK1 protein
[MAP2K1 protein results in increased phosphorylation of MAPK1 protein] which results in decreased susceptibility to sorafenib; [sorafenib co-treated with [IFNA2 protein co-treated with IFNA8 protein]] affects the phosphorylation of MAPK1 protein; [sorafenib co-treated with Cisplatin] results in decreased phosphorylation of MAPK1 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [sorafenib co-treated with rottlerin] results in decreased phosphorylation of MAPK1 protein; [sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK1 protein; sorafenib inhibits the reaction [arsenic trioxide results in increased activity of MAPK1 protein]; sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
CTD PMID:16109713, PMID:16255777, PMID:16959960, PMID:17178882, PMID:17205056, PMID:17341847, PMID:17664273, PMID:17991738, PMID:18200035, PMID:18819900, PMID:19129670, PMID:19139124, PMID:19338580, PMID:19366808, PMID:19633425, PMID:19878585, PMID:20054642, PMID:20071162, PMID:20117835, PMID:20301194, PMID:20473320, PMID:21187475, PMID:21693435, PMID:21813464, PMID:21858812, PMID:22963400, PMID:26333016 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk14 mitogen activated protein kinase 14 decreases expression ISO sorafenib results in decreased expression of MAPK14 protein modified form CTD PMID:16985072 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation
decreases activity
affects phosphorylation
ISO
EXP
[MAP2K1 protein results in increased phosphorylation of MAPK3 protein] which results in decreased susceptibility to sorafenib; [sorafenib co-treated with [IFNA2 protein co-treated with IFNA8 protein]] affects the phosphorylation of MAPK3 protein; [sorafenib co-treated with Cisplatin] results in decreased phosphorylation of MAPK3 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [sorafenib co-treated with rottlerin] results in decreased phosphorylation of MAPK3 protein; [sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK3 protein; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK3 protein; sorafenib inhibits the reaction [Acids results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [arsenic trioxide results in increased activity of MAPK3 protein]; sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
sorafenib results in increased phosphorylation of MAPK3 protein
sorafenib results in decreased expression of MAPK3 protein modified form
sorafenib results in decreased phosphorylation of MAPK3 protein
sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK3 protein modified form]; sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
Sorafenib results in decreased phosphorylation of MAPK3 protein
sorafenib results in decreased activity of MAPK3 protein
sorafenib affects the phosphorylation of MAPK3 protein
CTD PMID:16109713, PMID:16255777, PMID:16959960, PMID:17178882, PMID:17205056, PMID:17341847, PMID:17664273, PMID:17991738, PMID:18200035, PMID:18512153, PMID:18819900, PMID:19129670, PMID:19139124, PMID:19338580, PMID:19366808, PMID:19633425, PMID:19878585, PMID:20054642, PMID:20071162, PMID:20117835, PMID:20301194, PMID:20473320, PMID:21187475, PMID:21693435, PMID:21813464, PMID:21858812, PMID:22963400, PMID:26333016 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
decreases phosphorylation
ISO [Bortezomib co-treated with Sorafenib] results in increased phosphorylation of MAPK8 protein; licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAPK8 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAPK8 protein] CTD PMID:16985072, PMID:30187994 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions
decreases phosphorylation
ISO [Bortezomib co-treated with Sorafenib] results in increased phosphorylation of MAPK9 protein; licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAPK9 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAPK9 protein] CTD PMID:16985072, PMID:30187994 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
affects response to substance
increases degradation
decreases expression
decreases response to substance
ISO [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased expression of MCL1 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in decreased expression of MCL1 mRNA; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in decreased expression of MCL1 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein; [sorafenib co-treated with TNFSF10 protein] results in decreased expression of MCL1 protein; [sorafenib results in decreased phosphorylation of EIF4E protein] which results in decreased expression of MCL1; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]; MCL1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP9 protein]; MCL1 protein results in decreased susceptibility to [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide]; sorafenib results in increased degradation of and results in decreased expression of MCL1 protein
MCL1 protein affects the susceptibility to sorafenib
sorafenib results in increased degradation of MCL1 protein
sorafenib results in decreased expression of MCL1 protein
MCL1 protein results in decreased susceptibility to sorafenib
CTD PMID:16007148, PMID:16109713, PMID:16985072, PMID:17178882, PMID:17595328, PMID:17909059, PMID:17991738, PMID:18200035, PMID:19001435, PMID:19633425, PMID:19878585, PMID:20071162, PMID:20105315, PMID:20117835, PMID:20473320, PMID:20881478, PMID:21293487, PMID:21750559, PMID:23036488, PMID:28673964 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO sorafenib results in increased expression of MDM2 mRNA CTD PMID:26409325 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
JBrowse link
G Mknk1 MAPK interacting serine/threonine kinase 1 multiple interactions ISO sorafenib inhibits the reaction [MKNK1 protein results in increased phosphorylation of EIF4E protein] CTD PMID:16109713 NCBI chr 5:134,691,852...134,730,887
Ensembl chr 5:134,691,881...134,730,893
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein] CTD PMID:29859236 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Msn moesin increases phosphorylation EXP sorafenib results in increased phosphorylation of MSN protein CTD PMID:19338580 NCBI chr  X:65,226,834...65,294,192
Ensembl chr  X:65,226,748...65,295,810
JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases activity
increases phosphorylation
increases expression
decreases phosphorylation
multiple interactions
decreases expression
ISO sorafenib results in decreased activity of MTOR protein
sorafenib results in increased phosphorylation of MTOR protein
sorafenib results in increased expression of MTOR protein
sorafenib results in decreased phosphorylation of MTOR protein
[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib] results in decreased activity of MTOR protein; [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; [sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; arsenic trioxide inhibits the reaction [sorafenib results in increased expression of MTOR protein]
sorafenib results in decreased expression of MTOR mRNA
CTD PMID:20054642, PMID:21187475, PMID:21601561, PMID:23036488, PMID:25416439, PMID:26409325 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [sorafenib co-treated with letrozole] results in decreased expression of MYC protein; sorafenib inhibits the reaction [Acids results in increased expression of MYC protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of MYC protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of MYC protein] CTD PMID:17991738, PMID:18512153, PMID:20054642 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in decreased expression of NFKB1 protein] CTD PMID:29859236 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression ISO [sorafenib results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein CTD PMID:21109933 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nras NRAS proto-oncogene, GTPase decreases expression ISO sorafenib results in decreased expression of NRAS mRNA CTD PMID:26409325 NCBI chr 2:205,553,119...205,563,716
Ensembl chr 2:205,553,163...205,560,791
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein; [sorafenib co-treated with PRKN protein] results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; resveratrol promotes the reaction [sorafenib results in increased cleavage of PARP1 protein] CTD PMID:16985072, PMID:20054642, PMID:26911335, PMID:28673964 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pdgfra platelet derived growth factor receptor alpha decreases phosphorylation ISO sorafenib results in decreased phosphorylation of PDGFRA protein mutant form CTD PMID:21482694 NCBI chr14:35,527,926...35,581,130
Ensembl chr14:35,527,927...35,581,031
JBrowse link
G Pdgfrb platelet derived growth factor receptor beta multiple interactions
decreases expression
decreases phosphorylation
decreases activity
ISO
EXP
[Bortezomib co-treated with sorafenib] results in decreased phosphorylation of PDGFRB protein
sorafenib results in decreased phosphorylation of and results in decreased activity of PDGFRB protein
sorafenib results in decreased expression of PDGFRB mRNA
sorafenib results in decreased phosphorylation of PDGFRB protein
sorafenib results in decreased activity of PDGFRB protein mutant form
CTD PMID:16985072, PMID:17229632, PMID:19139124, PMID:19338580 NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha decreases expression ISO sorafenib results in decreased expression of PIK3C2A mRNA CTD PMID:26409325 NCBI chr 1:185,210,922...185,326,314
Ensembl chr 1:185,210,922...185,326,314
JBrowse link
G Pik3ca phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha decreases expression ISO sorafenib results in decreased expression of PIK3CA mRNA CTD PMID:26409325 NCBI chr 2:118,831,350...118,861,456
Ensembl chr 2:118,831,350...118,861,454
JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase multiple interactions ISO [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib co-treated with Oxygen deficiency] results in decreased expression of PIM1 protein; [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] inhibits the reaction [Oxygen deficiency results in increased expression of PIM1 protein]; [sorafenib co-treated with Oxygen deficiency] results in decreased expression of PIM1 protein; sorafenib inhibits the reaction [Oxygen deficiency results in increased expression of PIM1 protein] CTD PMID:23036488 NCBI chr20:8,165,423...8,169,557
Ensembl chr20:8,165,307...8,169,555
JBrowse link
G Pink1 PTEN induced kinase 1 multiple interactions
increases expression
affects response to substance
ISO [sorafenib co-treated with PRKN protein] results in increased expression of PINK1 protein; PINK1 protein affects the reaction [sorafenib affects the localization of PRKN protein]
sorafenib results in increased expression of PINK1 protein
PINK1 protein affects the susceptibility to sorafenib
CTD PMID:28673964 NCBI chr 5:156,677,146...156,689,258
Ensembl chr 5:156,677,146...156,689,415
JBrowse link
G Plau plasminogen activator, urokinase decreases expression
multiple interactions
ISO Sorafenib results in decreased expression of PLAU protein
licochalcone A promotes the reaction [Sorafenib results in decreased expression of PLAU protein]; Sorafenib promotes the reaction [licochalcone A results in decreased expression of PLAU protein]
CTD PMID:30187994 NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
JBrowse link
G Plk2 polo-like kinase 2 increases expression ISO sorafenib results in increased expression of PLK2 mRNA CTD PMID:26409325 NCBI chr 2:41,911,143...41,916,901
Ensembl chr 2:41,911,131...41,916,901
JBrowse link
G Plk3 polo-like kinase 3 increases expression ISO sorafenib results in increased expression of PLK3 mRNA CTD PMID:26409325 NCBI chr 5:135,997,725...136,002,900
Ensembl chr 5:135,997,725...136,002,900
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions
decreases expression
ISO 6-bromoindirubin-3'-oxime inhibits the reaction [sorafenib results in decreased expression of PMAIP1 protein] CTD PMID:17991738 NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO sorafenib results in increased expression of PPP1R15A protein CTD PMID:17548474 NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
JBrowse link
G Prkca protein kinase C, alpha decreases expression ISO sorafenib results in decreased expression of PRKCA mRNA CTD PMID:26409325 NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase increases ubiquitination
affects response to substance
multiple interactions
affects localization
ISO sorafenib results in increased ubiquitination of PRKN protein
PRKN protein affects the susceptibility to sorafenib
[sorafenib co-treated with PRKN protein] results in decreased expression of CASP3 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein; [sorafenib co-treated with PRKN protein] results in increased cleavage of PARP1 protein; [sorafenib co-treated with PRKN protein] results in increased expression of PINK1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; PINK1 protein affects the reaction [sorafenib affects the localization of PRKN protein]
CTD PMID:28673964 NCBI chr 1:48,880,015...50,069,998 JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases activity ISO sorafenib results in decreased activity of RAF1 protein CTD PMID:19139124, PMID:21531053 NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases expression
decreases phosphorylation
ISO [sorafenib co-treated with letrozole] results in decreased expression of RB1 protein
sorafenib results in decreased expression of RB1 protein
sorafenib results in decreased phosphorylation of RB1 protein
CTD PMID:17909054, PMID:19633425, PMID:20054642 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of RELA protein] CTD PMID:29859236 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Ret ret proto-oncogene decreases activity
increases degradation
ISO Sorafenib results in decreased activity of RET protein; Sorafenib results in decreased activity of RET protein mutant form
sorafenib results in increased degradation of RET protein
CTD PMID:17664273 NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
JBrowse link
G Rock1 Rho-associated coiled-coil containing protein kinase 1 decreases expression
increases expression
EXP sorafenib results in decreased expression of ROCK1 mRNA; sorafenib results in decreased expression of ROCK1 protein
sorafenib results in increased expression of ROCK1 protein
CTD PMID:19338580 NCBI chr18:1,273,490...1,390,790
Ensembl chr18:1,273,453...1,390,190
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions
ISO sorafenib results in decreased phosphorylation of RPS6 protein
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in decreased phosphorylation of RPS6 protein]
CTD PMID:23036488 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions
decreases phosphorylation
increases phosphorylation
ISO arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of RPS6KB1 protein]
Sorafenib results in decreased phosphorylation of RPS6KB1 protein
CTD PMID:21858812, PMID:25416439 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Serpinh1 serpin family H member 1 decreases expression EXP sorafenib results in decreased expression of SERPINH1 mRNA CTD PMID:24321339 NCBI chr 1:164,301,010...164,308,306
Ensembl chr 1:164,301,010...164,308,317
JBrowse link
G Sesn2 sestrin 2 increases expression ISO Sorafenib results in increased expression of SESN2 protein CTD PMID:31323261 NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
JBrowse link
G Slc13a5 solute carrier family 13 member 5 decreases response to substance ISO SLC13A5 protein results in decreased susceptibility to Sorafenib CTD PMID:32634519 NCBI chr10:58,806,581...58,835,549
Ensembl chr10:58,810,058...58,834,538
JBrowse link
G Smad2 SMAD family member 2 affects localization
multiple interactions
ISO sorafenib affects the localization of SMAD2 protein
sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]
CTD PMID:21360571 NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
JBrowse link
G Smad3 SMAD family member 3 affects localization
multiple interactions
ISO sorafenib affects the localization of SMAD3 protein
sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]
CTD PMID:21360571 NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
JBrowse link
G Smad7 SMAD family member 7 decreases expression ISO sorafenib results in decreased expression of SMAD7 mRNA CTD PMID:21360571 NCBI chr18:71,395,830...71,424,164
Ensembl chr18:71,395,830...71,424,157
JBrowse link
G Smpd1 sphingomyelin phosphodiesterase 1 multiple interactions ISO [vorinostat co-treated with sorafenib] promotes the reaction [SMPD1 protein results in increased abundance of Ceramides]; SMPD1 protein promotes the reaction [[vorinostat co-treated with sorafenib] affects the localization of FAS protein] CTD PMID:18787411 NCBI chr 1:170,383,682...170,387,525
Ensembl chr 1:170,383,682...170,387,524
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein] CTD PMID:21360571 NCBI chr 3:164,274,710...164,279,199
Ensembl chr 3:164,274,710...164,279,378
JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions
decreases expression
ISO destruxin B promotes the reaction [sorafenib results in decreased expression of SNAI2 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of SNAI2 protein] CTD PMID:24434019 NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO sorafenib results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:14,890,318...14,895,907
Ensembl chr 5:14,890,408...14,895,907
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression
ISO bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein] CTD PMID:21858812 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions
decreases activity
ISO sorafenib inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein]
sorafenib results in decreased activity of SRC protein
CTD PMID:20881478 NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
affects localization
decreases phosphorylation
ISO resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [Acids results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of STAT3 protein]; sorafenib results in decreased phosphorylation of and results in decreased activity of STAT3 protein
sorafenib affects the localization of STAT3 protein
sorafenib analog results in decreased phosphorylation of STAT3 protein; sorafenib results in decreased phosphorylation of STAT3 protein
CTD PMID:18512153, PMID:19001435, PMID:20881478, PMID:21360571, PMID:21531053, PMID:26911335 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Stat5a signal transducer and activator of transcription 5A decreases phosphorylation
multiple interactions
decreases activity
ISO sorafenib results in decreased phosphorylation of STAT5A protein
resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT5A protein]
sorafenib results in decreased activity of STAT5A protein
CTD PMID:17595328, PMID:23036488, PMID:26911335 NCBI chr10:88,764,732...88,789,060
Ensembl chr10:88,764,732...88,789,057
JBrowse link
G Stat5b signal transducer and activator of transcription 5B multiple interactions ISO resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT5B protein] CTD PMID:26911335 NCBI chr10:88,686,207...88,712,313
Ensembl chr10:88,686,207...88,754,829
JBrowse link
G Stc1 stanniocalcin 1 decreases expression
multiple interactions
ISO sorafenib results in decreased expression of STC1 mRNA
STC1 affects the reaction [sorafenib results in increased abundance of Reactive Oxygen Species]
CTD PMID:25370841 NCBI chr15:50,891,137...50,901,791
Ensembl chr15:50,891,127...50,903,162
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases expression
decreases activity
ISO Sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of TJP1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased activity of CASP3 mRNA]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL4A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of STAT3 protein]
sorafenib results in decreased expression of TGFB1 mRNA
sorafenib results in decreased activity of TGFB1 protein
Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of TGFB1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]
CTD PMID:21360571, PMID:29859236 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Timp3 TIMP metallopeptidase inhibitor 3 decreases expression ISO sorafenib results in decreased expression of TIMP3 mRNA CTD PMID:21360571 NCBI chr 7:23,543,125...23,594,170
Ensembl chr 7:23,544,215...23,594,133
JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of TJP1 protein] CTD PMID:21360571 NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of TNF protein] CTD PMID:29859236 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions
increases response to substance
ISO [[Sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein; [Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of AIFM1 protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of BAX protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of DIABLO protein; [Sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of BCL2L1 protein; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of MCL1 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP7 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of XIAP protein; [Sorafenib results in decreased expression of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; [Sorafenib results in increased degradation of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; MCL1 protein inhibits the reaction [[Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; MCL1 protein inhibits the reaction [[Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]
sorafenib results in increased susceptibility to TNFSF10 protein
CTD PMID:17909059, PMID:20071162, PMID:21601561 NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of TP53 protein] CTD PMID:17991738 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Tsc2 TSC complex subunit 2 multiple interactions EXP sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of EIF4EBP1 protein modified form]; sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK1 protein modified form]; sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK3 protein modified form]; sorafenib inhibits the reaction [TSC2 protein mutant form results in increased expression of CCND1 protein] CTD PMID:21813464 NCBI chr10:13,962,006...13,996,684
Ensembl chr10:13,961,947...13,996,584
JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases expression ISO sorafenib results in decreased expression of TWIST1 mRNA CTD PMID:21360571 NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
JBrowse link
G Txnrd1 thioredoxin reductase 1 increases expression ISO sorafenib results in increased expression of TXNRD1 mRNA CTD PMID:26409325 NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of VEGFA protein] CTD PMID:29859236 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vim vimentin multiple interactions
decreases expression
ISO destruxin B promotes the reaction [sorafenib results in decreased expression of VIM protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of VIM protein] CTD PMID:21360571, PMID:24434019 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Xbp1 X-box binding protein 1 increases splicing ISO sorafenib results in increased splicing of XBP1 mRNA CTD PMID:17548474 NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression
increases cleavage
multiple interactions
ISO sorafenib results in decreased expression of XIAP protein
sorafenib results in increased cleavage of XIAP protein
[sorafenib co-treated with TNFSF10 protein] results in increased cleavage of XIAP protein
CTD PMID:16109713, PMID:17909059, PMID:18200035 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
G Yap1 Yes1 associated transcriptional regulator decreases response to substance ISO YAP1 protein results in decreased susceptibility to sorafenib CTD PMID:29698666 NCBI chr 8:6,133,014...6,204,240
Ensembl chr 8:6,135,493...6,203,579
JBrowse link
G Zeb1 zinc finger E-box binding homeobox 1 decreases expression ISO sorafenib results in decreased expression of ZEB1 mRNA CTD PMID:21360571 NCBI chr17:54,656,627...54,714,920
Ensembl chr17:54,658,463...54,714,914
JBrowse link
G Zeb2 zinc finger E-box binding homeobox 2 decreases expression ISO sorafenib results in decreased expression of ZEB2 mRNA CTD PMID:21360571 NCBI chr 3:29,857,289...29,985,932
Ensembl chr 3:29,862,473...29,996,865
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19787
    role 19734
      biological role 19734
        antimicrobial agent 17312
          antiviral agent 10246
            anticoronaviral agent 8941
              sorafenib 156
                sorafenib tosylate 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19787
    subatomic particle 19784
      composite particle 19784
        hadron 19784
          baryon 19784
            nucleon 19784
              atomic nucleus 19784
                atom 19784
                  main group element atom 19672
                    p-block element atom 19672
                      carbon group element atom 19574
                        carbon atom 19563
                          organic molecular entity 19563
                            organic group 18495
                              organic divalent group 18488
                                organodiyl group 18488
                                  carbonyl group 18391
                                    carbonyl compound 18391
                                      carboxylic acid 18061
                                        carboacyl group 17348
                                          univalent carboacyl group 17348
                                            carbamoyl group 17134
                                              carboxamide 17134
                                                monocarboxylic acid amide 14553
                                                  urea 4984
                                                    ureas 4982
                                                      phenylureas 1976
                                                        sorafenib 156
                                                          sorafenib tosylate 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.